Perseus Proteomics is a biotech venture aiming at antibody
drug discovery utilizing its unique antibody technologies
for people suffering from diseases throughout the world. Established with a strong academic background from collaborations with the University of Tokyo, the company leverages a proprietary antibody discovery platform and deep proteomic expertise to identify disease-specific targets. Their focus is on the treatment of cancers, autoimmune diseases, and other intractable conditions. Perseus Proteomics is engaged in the entire drug development process—from basic research through preclinical and clinical development—often working in close partnerships with pharmaceutical and academic institutions. They also offer licensing opportunities and pursue commercialization strategies through both internal pipelines and collaborative ventures.